SCHEMBL3309883

SCHEMBL3309883

OCc1ccc(F)cc1CO

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.40
AGXT P21549 2/20 0.40
CA3 P07451 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
TYR P14679 1/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
KDM4E B2RXH2 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CES2 O00748 2/20 0.34
CES1 P23141 2/20 0.34
GRIA1 P42261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31085527 1.00 IDO1 (0.40) IDO1AGXTCA3CA6CA5A
SCHEMBL6441169 0.86 MAPT (0.39) IDO1AGXTSLC6A2SLC6A4KDM4E
SCHEMBL5655880 0.86 MPO (0.43) IDO1AGXTCA3CA6CA5A
SCHEMBL13548272 0.86 MAPT (0.39) IDO1AGXTPDE4APDE4BPDE4C
SCHEMBL8121079 0.86 IDO1 (0.35) IDO1AGXTCA3CA6CA5A
SCHEMBL4921376 0.86 MPO (0.43) IDO1AGXTCA3CA6CA5A
SCHEMBL27310 0.86 TYR (0.37) IDO1AGXTCA3CA6CA5A
SCHEMBL17355055 0.83 F2RL1 (0.42) TYR
SCHEMBL7667398 0.83 IDO1 (0.37) IDO1AGXTCA3CA6CA5A
SCHEMBL16961174 0.83 F2RL1 (0.42) PDE4APDE4BPDE4CPDE4DTYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4644384-A1 CYP11A1 INHIBITOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Lichun Biotech Co., Ltd. (CN) 2025-11-05 EP disclosed
WO-2024146383-A1 CYP11A1 INHIBITOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海闻耐医药科技有限公司 2024-07-11 WO disclosed
CN-118307519-A CYP11A1 inhibitor compound, preparation method and application thereof 上海闻耐医药科技有限公司 2024-07-09 CN disclosed
US-11312726-B2 Thienodiazepine derivatives and application thereof CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2022-04-26 US disclosed
US-20210024605-A1 CYCLIC PEPTIDE ANALOGS OF MELANOCORTIN AND AMANITIN AND METHODS OF MAKING SUCH PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2021-01-28 US disclosed
US-20210017190-A1 THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2021-01-21 US disclosed
US-20200239452-A1 IDO/TDO Inhibitor CANBAS CO., LTD. (JP) 2020-07-30 US disclosed
WO-2019078246-A1 IDO/TDO INHIBITOR 一般社団法人ファルマバレープロジェクト支援機構 2019-04-25 WO disclosed
CN-101679346-B Substituted benzoylamino-indan-2-carboxylic acids and related compounds SANOFI-AVENTIS (FR) 2014-10-22 CN disclosed
US-8569535-B2 Substituted benzoylamino-indan-2-carboxylic acids and related compounds SANOFI (FR) 2013-10-29 US disclosed
WO-2008151211-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS SANOFI-AVENTIS (FR) 2008-12-11 WO disclosed
US-7220743-B2 Heterocyclic CB1 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2007-05-22 US disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed
EP-0238753-B1 N-SUBSTITUTED CONDENSED POLYMETHYLENE IMINE DERIVATIVES BEECHAM GROUP PLC (GB) 1992-01-15 EP disclosed
US-4959374-A HYPOTENSIVE AGENTS, ANTICOAGULANTS, GLAUCOMA, HYPERGLYCEMIC AGENTS, ANTIDEPRESSANTS BEECHAM GROUP P.L.C. (GB) 1990-09-25 US disclosed
US-4863946-A HYPOGLYCEMIC AND HYPOTENSIVE AGENTS BEECHAM GROUP PLC (GB) 1989-09-05 US disclosed
EP-0238753-A1 N-substituted condensed polymethylene imine derivatives BEECHAM GROUP PLC (GB) 1987-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017190-A1 THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF BRD4, BRD3, BRD2 IDO1 609/4885AGXT 3749/4885CA3 3786/4885
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 IDO1 1657/4885AGXT 2941/4885CA3 4873/4885
US-20200239452-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 IDO1 1/4885AGXT 263/4885CA3 629/4885
US-20210024605-A1 CYCLIC PEPTIDE ANALOGS OF MELANOCORTIN AND AMANITIN AND METHODS OF MAKING SUCH MC3R, MC5R, MC4R IDO1 300/4885AGXT 2366/4885CA3 1202/4885
US-11312726-B2 Thienodiazepine derivatives and application thereof BRD4, BRD3, BRD2 IDO1 609/4885AGXT 3749/4885CA3 3786/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 IDO1 1267/4885AGXT 2620/4885CA3 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.